DATASEA INC.

DATASEA INC. Annual Report Summary - Straight Talk for Investors

Let’s cut through the noise and see how DATASEA (NASDAQ: DTSS) performed this year—no jargon, just clear insights for everyday investors.

---

What Does DATASEA Do?

DATASEA is a Nevada-based tech company with two core divisions:

1. AI Cybersecurity Tools (protecting data like a digital bodyguard).
2. Acoustic Tech (using sound waves for healthcare devices, smart farming sensors, and industrial gear).

This Year’s Big Move: They merged sound tech with AI to create smart solutions, like:

• Non-drug medical therapies using sound waves to influence brain/heart activity.
• Full health scans → diagnosis → treatment systems powered by acoustics.

But Watch Out: 80%+ of operations run through China using a risky legal setup (VIE). If Chinese regulators challenge this structure, shareholders could lose everything overnight.

---

Financial Performance: Growth vs. Reality

Revenue Tripled to $71.6 Million (up 199% from $24M last year) thanks to:

• Strong demand for AI security tools.
• New acoustic products like ultrasound medical devices.

But Profit? A $56.8 Million Loss (down from an $8M profit last year). Here’s why:

• R&D Spending Exploded: $18.4 million (up 250%) to develop medical tech like brain-regulation devices.
• Admin Costs Doubled: $4.05 million spent on global expansion.
• Taxes Paid: $95,918 despite losses.

Hidden Complexity: About 0.88% of revenue ($633k) came from internal deals with their Chinese subsidiary. If China restricts these transactions, that income could disappear.

---

Wins vs. Challenges

Wins 🏆:

• Launched acoustic tech in hospitals (for brain/heart therapy), farms, and factories.
• Expanded into 5 industries, including the $50B+ non-drug medical market.
• Opened a U.S. branch (Datasea Acoustics LLC) to sell products stateside.

Challenges 🚩:

• VIE Time Bomb: China could disrupt their U.S. stock listing. If their Chinese subsidiary can’t pay debts, DATASEA must cover them.
• Cash Burn: Spent $2.50 for every $1 earned. Total lifetime losses hit $44.5 million.
• Governance Questions: The company didn’t provide much detail about director independence, raising concerns about oversight.

---

Financial Health Check

• Cash: $30M (down from $50M last year).
• Debt: $80M total, including $1.17M in short-term loans.
• Assets: $27.1M (up from $13.9M last year)—they’re investing in patents and tech.
• Public Float: $16.4M worth of shares available to investors.

Verdict: Growing fast but burning cash. Their R&D bets (like sound-based medical devices) could pay off—or leave them strapped.

---

Top Risks to Know

1. China’s VIE Crackdowns: A regulatory move could wipe out shareholders.
2. Internal Deal Dependencies: 0.88% of revenue relies on fragile China-U.S. transactions.
3. Supplier Costs: Rising material prices could squeeze profits further.
4. Economic Exposure: 80% of business ties to China’s slowing economy.

---

What’s Next?

• Launching acoustic tech in U.S. hospitals and smart farms.
• Rolling out new AI security tools and IoT farming sensors.
• Make-or-Break: Turning R&D projects (like brain-computer interfaces) into market-ready products.

---

Bottom Line for Investors

High Risk, High Reward:

• ✅ Why Buy? Revenue tripled, acoustic tech is breaking into healthcare, and AI tools are in demand.
• ❌ Why Avoid? China risks loom large, cash burn is extreme, and governance questions linger.

Think of it like: Investing in a rocket ship—it could soar, but there’s a real chance it crashes if China pulls the plug or R&D stalls.

---

This summary simplifies complex filings—always do your own research or consult a financial advisor. ☕